Andrew J. Armstrong, MD

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Andrew J. Armstrong, MD sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).

5 total trials none currently recruiting 3 completed early-phase tilt upper quartile by trial count

Andrew J. Armstrong, MD: 5 sponsored US clinical trials, none currently recruiting.

Andrew J. Armstrong, MD sponsors 5 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 3 completed. 0 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Metastatic Prostate Neuroendocrine Carcinoma, with 1 trials.

Upper-quartile sponsor footprint

Andrew J. Armstrong, MD sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

5 total, page 1 of 1

ACTIVE NOT RECRUITING Phase 2

A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer

NCT04709276
COMPLETED Phase 2

A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)

NCT03311555
COMPLETED Phase 2

PD-L1 Inhibition as ChecKpoint Immunotherapy for NeuroEndocrine Phenotype Prostate Cancer

NCT03179410
COMPLETED Phase 1

The CATCH Prostate Cancer Trial: Cabazitaxel And Tasquinimod in Men With Prostate Cancer

NCT01513733
TERMINATED Phase 2

BKM120 in Metastatic Castration-resistant Prostate Cancer

NCT01385293

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 4

Therapeutic Areas

Metastatic Prostate Neuroendocrine Carcinoma 1
Metastatic Prostate Cancer 1

How the Andrew J. Armstrong, MD early-phase archive is shaped

5 indexed studies, none listed as recruiting (0% open); 3 completed (60%).

Phase mix: 0 late (III/IV) vs 5 early (I/II) (early-phase heavy).

Top condition: Metastatic Prostate Neuroendocrine Carcinoma (1 trial), 1 other listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Andrew J. Armstrong, MD: archived-pipeline peers nationwide

Peers matched on 5 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Andrew J. Armstrong, MD sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%5%10%15%20%25% Total trials Recruiting share Andrew J. Armstrong, MD4YouandMeAbbott Rapid DxAccess Business GroupAcera Surgical10xBio22nd Century Group23andMe3-C Institute for Social Development
Andrew J. Armstrong, MD sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Andrew J. Armstrong, MD sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 5 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Andrew J. Armstrong, MD page

5 registered trials is a research-attention snapshot, not an endorsement of Andrew J. Armstrong, MD or any single study.

  • None of Andrew J. Armstrong, MD's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Metastatic Prostate Neuroendocrine Carcinoma is the condition Andrew J. Armstrong, MD studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Metastatic Prostate Neuroendocrine Carcinoma trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Andrew J. Armstrong, MD pipeline card: 5 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.